Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Anakinra/hydroxychloroquine

Rebound effect, lack of efficacy and off-label use

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Omenetti A, et al. Clinical disease course of family members with unknown SAVI-like vasculopathy. Pediatric Rheumatology 21 (Suppl. 2): 239 abstr. P344, Oct 2023. Available from: URL: https://dx.doi.org/10.1186/s12969-023-00879-8 [abstract] Omenetti A, et al. Clinical disease course of family members with unknown SAVI-like vasculopathy. Pediatric Rheumatology 21 (Suppl. 2): 239 abstr. P344, Oct 2023. Available from: URL: https://dx.doi.org/10.1186/s12969-023-00879-8 [abstract]
Metadaten
Titel
Anakinra/hydroxychloroquine
Rebound effect, lack of efficacy and off-label use
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-55904-6

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Morphine

Case report

Denosumab

Case report

Pembrolizumab